menu search

BMRN / BioMarin Pharmaceutical (BMRN) Q4 Earnings Lag Estimates

BioMarin Pharmaceutical (BMRN) Q4 Earnings Lag Estimates
BioMarin (BMRN) delivered earnings and revenue surprises of -7.69% and 0.69%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock? Read More
Posted: Feb 27 2023, 18:49
Author Name: Zacks Investment Research
Views: 110864

BMRN News  

Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Call Transcript

By Seeking Alpha
November 1, 2023

Biomarin Pharmaceutical, Inc. (BMRN) Q3 2023 Earnings Call Transcript

Biomarin Pharmaceutical, Inc. (NASDAQ:BMRN ) Q3 2023 Earnings Conference Call November 1, 2023 4:30 PM ET Company Participants Traci McCarty - Head of more_horizontal

U.S. FDA approves expanded use of BioMarin's dwarfism therapy

By Reuters
October 20, 2023

U.S. FDA approves expanded use of BioMarin's dwarfism therapy

The U.S. Food and Drug Administration (FDA) on Friday approved the expanded use of BioMarin Pharmaceutical's once-daily injection to treat children un more_horizontal

BioMarin: Growth Drivers Remain Intact

By Seeking Alpha
October 19, 2023

BioMarin: Growth Drivers Remain Intact

During Q2 2023, BioMarin Pharmaceutical's revenues for the quarter has reached $595.3 million, a 12% YoY increase. The company's drug pipeline include more_horizontal

Why BioMarin (BMRN) Could Beat Earnings Estimates Again

By Zacks Investment Research
October 18, 2023

Why BioMarin (BMRN) Could Beat Earnings Estimates Again

BioMarin (BMRN) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat more_horizontal

CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants

By Zacks Investment Research
September 18, 2023

CHMP Endorses BioMarin's (BMRN) Voxzogo for Use in Infants

A final decision study on BioMarin's (BMRN) Voxzogo to treat children above four months with achondroplasia is expected before year's end. more_horizontal

BioMarin: Q2 2023 Confirmed My Bullish View

By Seeking Alpha
August 5, 2023

BioMarin: Q2 2023 Confirmed My Bullish View

BioMarin's 2Q23 revenue rose 12% YoY to $595 million, with adjusted EBITDA at $135 million. Revenues of the mucopolysaccharidosis drug portfolio decre more_horizontal

BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales

By Zacks Investment Research
August 1, 2023

BioMarin (BMRN) Q2 Earnings & Sales Top, Voxzogo Drives Sales

BioMarin (BMRN) beats on earnings and sales estimates in the second quarter on the back of robust demand for Voxzogo. more_horizontal

BioMarin (BMRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

By Zacks Investment Research
July 31, 2023

BioMarin (BMRN) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

Although the revenue and EPS for BioMarin (BMRN) give a sense of how its business performed in the quarter ended June 2023, it might be worth consider more_horizontal


Search within

Pages Search Results: